Rising Revlimid Demand Helps Celgene's Second-Quarter EPS
Celgene Corp., of Summit, N.J., exceeded analysts' estimates modestly in its second-quarter earnings report, turning in total revenues of $1.367 billion, a 16 percent increase over the second quarter of 2011. Those revenue increases were led by growing sales of multiple myeloma blockbuster Revlimid (lenolidomide).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST